Search

Your search keyword '"Ćwikła, Jarosław B."' showing total 157 results
Start Over Author "Ćwikła, Jarosław B."
157 results on '"Ćwikła, Jarosław B."'

1. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

Author

Nesti, Cédric, Bräutigam, Konstantin, Benavent, Marta, Bernal, Laura, Boharoon, Hessa, Botling, Johan, Bouroumeau, Antonin, Brcic, Iva, Brunner, Maximilian, Cadiot, Guillaume, Camara, Maria, Christ, Emanuel, Clerici, Thomas, Clift, Ashley K, Clouston, Hamish, Cobianchi, Lorenzo, Ćwikła, Jarosław B, Daskalakis, Kosmas, Frilling, Andrea, Garcia-Carbonero, Rocio, Grozinsky-Glasberg, Simona, Hernando, Jorge, Hervieu, Valérie, Hofland, Johannes, Holmager, Pernille, Inzani, Frediano, Jann, Henning, Jimenez-Fonseca, Paula, Kaçmaz, Enes, Kaemmerer, Daniel, Kaltsas, Gregory, Klimacek, Branislav, Knigge, Ulrich, Kolasińska-Ćwikła, Agnieszka, Kolb, Walter, Kos-Kudła, Beata, Kunze, Catarina Alisa, Landolfi, Stefania, La Rosa, Stefano, López, Carlos López, Lorenz, Kerstin, Matter, Maurice, Mazal, Peter, Mestre-Alagarda, Claudia, del Burgo, Patricia Morales, van Dijkum, Els J M Nieveen, Oleinikov, Kira, Orci, Lorenzo A, Panzuto, Francesco, Pavel, Marianne, Perrier, Marine, Reims, Henrik Mikael, Rindi, Guido, Rinke, Anja, Rinzivillo, Maria, Sagaert, Xavier, Satiroglu, Ilker, Selberherr, Andreas, Siebenhüner, Alexander R, Tesselaar, Margot E T, Thalhammer, Michael J, Thiis-Evensen, Espen, Toumpanakis, Christos, Vandamme, Timon, van den Berg, José G, Vanoli, Alessandro, van Velthuysen, Marie-Louise F, Verslype, Chris, Vorburger, Stephan A, Lugli, Alessandro, Ramage, John, Zwahlen, Marcel, Perren, Aurel, and Kaderli, Reto M

Published
2023
Full Text
View/download PDF

4. The Role of Receptor–Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.

Author

Milewska-Kranc, Agnieszka, Ćwikła, Jarosław B., and Kolasinska-Ćwikła, Agnieszka

Subjects
*CELL receptors, *CELLULAR signal transduction, *GENE expression, *RADIONUCLIDE imaging, *TREATMENT effectiveness, *SOMATOSTATIN, *NEUROENDOCRINE tumors, *LIGANDS (Biochemistry), *TUMOR grading
Abstract

Simple Summary: The tissue expression of somatostatin receptor (SSTR) subtypes in neuroendocrine tumors (NETs) holds paramount significance with far-reaching diagnostic and therapeutic implications. SSTRs contribute significantly to localizing NETs, aiding in advanced imaging techniques such as somatostatin receptor scintigraphy and PET scans. Elevated SSTR expression often aligns with less aggressive tumors, impacting tumor grading and influencing treatment decisions. Therapeutically, SSTRs serve as pivotal targets for treatments like targeted radiotherapy and synthetic somatostatin analogs (e.g., octreotide), commonly employed to inhibit hormone secretion and suppress tumor growth. Tailoring treatment strategies based on SSTR subtype expression enhances therapeutic efficacy. SSTR expression serves as a valuable prognostic indicator, predicting treatment response. While challenges like tumor heterogeneity persist, ongoing research explores promising avenues, including combination therapies. In conclusion, a nuanced understanding of SSTR expression in NETs is indispensable for precise diagnosis and the development of tailored therapeutic interventions, offering the potential for improved patient outcomes. Neuroendocrine tumors (NETs) arise from neuroendocrine cells and manifest in diverse organs. Key players in their regulation are somatostatin and its receptors (SSTR1–SSTR5). Understanding receptor–ligand interactions and signaling pathways is vital for elucidating their role in tumor development and therapeutic potential. This review highlights SSTR characteristics, localization, and expression in tissues, impacting physiological functions. Mechanisms of somatostatin and synthetic analogue binding to SSTRs, their selectivity, and their affinity were analyzed. Upon activation, somatostatin initiates intricate intracellular signaling, involving cAMP, PLC, and MAP kinases and influencing growth, differentiation, survival, and hormone secretion in NETs. This review explores SSTR expression in different tumor types, examining receptor activation effects on cancer cells. SSTRs' significance as therapeutic targets is discussed. Additionally, somatostatin and analogues' role in hormone secretion regulation, tumor growth, and survival is emphasized, presenting relevant therapeutic examples. In conclusion, this review advances the knowledge of receptor–ligand interactions and signaling pathways in somatostatin receptors, with potential for improved neuroendocrine tumor treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set

Author

Kolasińska-Ćwikła, Agnieszka, primary, Gutowska, Klaudia, additional, Osowiecka, Karolina, additional, Bednarczuk, Tomasz, additional, Słoniewska, Anna, additional, Roszkowska-Purska, Katarzyna, additional, Pałucki, Jakub, additional, and Ćwikła, Jarosław B., additional

Published
2022
Full Text
View/download PDF

10. Gastroduodenal neuroendocrine neoplasms including gastrinoma — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — uaktualnione zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]

Author

Rydzewska, Grażyna, primary, Strzelczyk, Janusz, additional, Bednarczuk, Tomasz, additional, Bolanowski, Marek, additional, Borowska, Małgorzata, additional, Chmielik, Ewa, additional, Ćwikła, Jarosław B., additional, Foltyn, Wanda, additional, Gisterek, Iwona, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Janas, Ksenia, additional, Jarząb, Michał, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kołos, Magorzata, additional, Kowalska, Aldona, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lewiński, Andrzej, additional, Liszka, Łukasz, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Malczewska, Anna, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pavel, Marianne E., additional, Pilch-Kowalczyk, Joanna, additional, Reguła, Jarosław, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Stojčev, Zoran, additional, Studniarek, Michał, additional, Syrenicz, Anhelli, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, Zieniewicz, Krzysztof, additional, and Kos-Kudła, Beata, additional

Published
2022
Full Text
View/download PDF

11. Colorectal neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita grubego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]

Author

Starzyńska, Teresa, primary, Londzin-Olesik, Magdalena, additional, Bednarczuk, Tomasz, additional, Bolanowski, Marek, additional, Borowska, Małgorzata, additional, Chmielik, Ewa, additional, Ćwikła, Jarosław B., additional, Foltyn, Wanda, additional, Gisterek, Iwona, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Michał, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lewiński, Andrzej, additional, Liszka, Łukasz, additional, Marek, Bogdan, additional, Malczewska, Anna, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pavel, Marianne E., additional, Pilch-Kowalczyk, Joanna, additional, Reguła, Jarosław, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Rydzewska, Grażyna, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Stojčev, Zoran, additional, Strzelczyk, Janusz, additional, Studniarek, Michał, additional, Syrenicz, Anhelli, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, Zieniewicz, Krzysztof, additional, and Kos-Kudła, Beata, additional

Published
2022
Full Text
View/download PDF

12. Neuroendocrine neoplasms of the small intestine and the appendix — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]

Author

Bednarczuk, Tomasz, primary, Zemczak, Anna, additional, Bolanowski, Marek, additional, Borowska, Małgorzata, additional, Chmielik, Ewa, additional, Ćwikła, Jarosław B., additional, Foltyn, Wanda, additional, Gisterek, Iwona, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Michał, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kopacz-Wróbel, Karolina, additional, Kowalska, Aldona, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lewiński, Andrzej, additional, Liszka, Łukasz, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Malczewska, Anna, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pavel, Marianne E., additional, Pilch-Kowalczyk, Joanna, additional, Reguła, Jarosław, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Rydzewska, Grażyna, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Stojčev, Zoran, additional, Strzelczyk, Janusz, additional, Studniarek, Michał, additional, Syrenicz, Anhelli, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zgliczyński, Wojciech, additional, Zieniewicz, Krzysztof, additional, and Kos-Kudła, Beata, additional

Published
2022
Full Text
View/download PDF

13. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]

Author

Kos-Kudła, Beata, primary, Foltyn, Wanda, additional, Malczewska, Anna, additional, Bednarczuk, Tomasz, additional, Bolanowski, Marek, additional, Borowska, Małgorzata, additional, Chmielik, Ewa, additional, Ćwikła, Jarosław B., additional, Gisterek, Iwona, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Barbara, additional, Jarząb, Michał, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Królicki, Leszek, additional, Krzakowski, Maciej, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lewiński, Andrzej, additional, Liszka, Łukasz, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pavel, Marianne E., additional, Pilch-Kowalczyk, Joanna, additional, Reguła, Jarosław, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Rydzewska, Grażyna, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Stojčev, Zoran, additional, Strzelczyk, Janusz, additional, Studniarek, Michał, additional, Syrenicz, Anhelli, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, and Zieniewicz, Krzysztof, additional

Published
2022
Full Text
View/download PDF

14. Pancreatic neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]

Author

Kos-Kudła, Beata, primary, Rosiek, Violetta, additional, Borowska, Małgorzata, additional, Bednarczuk, Tomasz, additional, Bolanowski, Marek, additional, Chmielik, Ewa, additional, Ćwikła, Jarosław B., additional, Foltyn, Wanda, additional, Gisterek, Iwona, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Michał, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lewiński, Andrzej, additional, Liszka, Łukasz, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Malczewska, Anna, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pavel, Marianne E., additional, Pilch-Kowalczyk, Joanna, additional, Reguła, Jarosław, additional, Ruchała, Marek, additional, Rydzewska, Grażyna, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Stojčev, Zoran, additional, Strzelczyk, Janusz, additional, Studniarek, Michał, additional, Syrenicz, Anhelli, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, and Zieniewicz, Krzysztof, additional

Published
2022
Full Text
View/download PDF

15. Outcomes of cardiac surgical treatment for carcinoid heart disease

Author

Konsek-Komorowska, Sonia J, primary, Kolasińska-Ćwikła, Agnieszka D, additional, Różański, Jacek, additional, Bartuś, Krzysztof, additional, Kuriata, Jarosław, additional, Konka, Marek, additional, Sitkowska-Rysiak, Ewa, additional, Michałowska, Ilona, additional, Florczak, Elżbieta, additional, Jaworska-Wilczyńska, Maria, additional, Januszewicz, Andrzej, additional, Hryniewiecki, Tomasz, additional, Ćwikła, Jarosław B, additional, and Pęczkowska, Mariola, additional

Published
2022
Full Text
View/download PDF

19. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Author

Caplin, Martyn E., Pavel, Marianne, Ćwikła, Jarosław B., Phan, Alexandria T., Raderer, Markus, Sedláčková, Eva, Cadiot, Guillaume, Wolin, Edward M., Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Langley, Alison, Martinez, Séverine, Blumberg, Joëlle, and Ruszniewski, Philippe

Published
2014
Full Text
View/download PDF

20. Nowotwory neuroendokrynne jelita grubego -- uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych).

Author

Starzyńska, Teresa, Londzin-Olesik, Magdalena, Bednarczuk, Tomasz, Bolanowski, Marek, Borowska, Małgorzata, Chmielik, Ewa, Ćwikła, Jarosław B., Foltyn, Wanda, Gisterek, Iwona, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Jarząb, Michał, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kolasińska-Ćwikła, Agnieszka, Kowalska, Aldona, Królicki, Leszek, Kunikowska, Jolanta, and Kuśnierz, Katarzyna

Published
2022
Full Text
View/download PDF

21. Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego -- uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych).

Author

Bednarczuk, Tomasz, Zemczak, Anna, Bolanowski, Marek, Borowska, Małgorzata, Chmielik, Ewa, Ćwikła, Jarosław B., Foltyn, Wanda, Gisterek, Iwona, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Jarząb, Michał, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kolasińska-Ćwikła, Agnieszka, Kopacz-Wróbel, Karolina, Kowalska, Aldona, Królicki, Leszek, Kunikowska, Jolanta, and Kuśnierz, Katarzyna

Published
2022
Full Text
View/download PDF

22. Nowotwory neuroendokrynne trzustki -- uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych).

Author

Kos-Kudła, Beata, Rosiek, Violetta, Borowska, Małgorzata, Bednarczuk, Tomasz, Bolanowski, Marek, Chmielik, Ewa, Ćwikła, Jarosław B., Foltyn, Wanda, Gisterek, Iwona, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Jarząb, Michał, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kolasińska-Ćwikła, Agnieszka, Kowalska, Aldona, Królicki, Leszek, Kunikowska, Jolanta, and Kuśnierz, Katarzyna

Published
2022
Full Text
View/download PDF

23. Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma -- uaktualnione zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych).

Author

Rydzewska, Grażyna, Strzelczyk, Janusz, Bednarczuk, Tomasz, Bolanowski, Marek, Borowska, Małgorzata, Chmielik, Ewa, Ćwikła, Jarosław B., Foltyn, Wanda, Gisterek, Iwona, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Janas, Ksenia, Jarząb, Michał, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kolasińska-Ćwikła, Agnieszka, Kołos, Małgorzata, Kowalska, Aldona, and Królicki, Leszek

Published
2022
Full Text
View/download PDF

24. Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowanych przez Polską Sieć Guzów Neuroendokrynnych).

Author

Kos-Kudła, Beata, Foltyn, Wanda, Malczewska, Anna, Bednarczuk, Tomasz, Bolanowski, Marek, Borowska, Małgorzata, Chmielik, Ewa, Ćwikła, Jarosław B., Gisterek, Iwona, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Jarząb, Barbara, Jarząb, Michał, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kolasińska-Ćwikła, Agnieszka, Kowalska, Aldona, Królicki, Leszek, and Krzakowski, Maciej

Published
2022
Full Text
View/download PDF

28. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms

Author

Matar, Somer, primary, Malczewska, Anna, additional, Oberg, Kjell, additional, Bodei, Lisa, additional, Aslanian, Harry, additional, Lewczuk-Myślicka, Anna, additional, Filosso, Pier Luigi, additional, Suarez, Alejandro L., additional, Kolasińska-Ćwikła, Agnieszka, additional, Roffinella, Matteo, additional, Kos-Kudła, Beata, additional, Ćwikła, Jarosław B., additional, Drozdov, Ignat A., additional, Kidd, Mark , additional, and Modlin, Irvin M., additional

Published
2019
Full Text
View/download PDF

29. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.

Author

Caplin, Martyn E., Pavel, Marianne, Phan, Alexandria T., Ćwikła, Jarosław B., Sedláčková, Eva, Thanh, Xuan-Mai Truong, Wolin, Edward M., and Ruszniewski, Philippe

Abstract

Purpose: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). The aim of CLARINET open-label extension (OLE) (NCT00842348) was to evaluate long-term safety and efficacy of lanreotide in these patients. Methods: Patients from the CLARINET study were eligible for the OLE if they had stable disease (irrespective of treatment group) or progressive disease (PD) (placebo-treated patients only). All patients in the OLE received lanreotide 120 mg every 28 days. Computed tomography or magnetic resonance imaging scans were conducted every 6 months and assessed locally for PD (the final scan was also assessed centrally). Results: Overall, 89 patients took part in the OLE (lanreotide, n = 42; placebo, n = 47). Median (range) exposure to lanreotide in patients who received lanreotide in the core study and OLE (LAN–LAN group) was 59.0 (26.0–102.3) months. In this group, the overall incidences of adverse events (AEs) and treatment-related AEs were lower in the OLE than in the core study. Median [95% CI] PFS in the LAN–LAN group was 38.5 [30.9; 59.4] months. In placebo-treated patients with PD at the end of the core study, time to death or subsequent PD during the OLE was 19 [10.1; 26.7] months. Conclusions: This study provides new evidence on the long-term safety profile and sustained anti-tumour effects of lanreotide autogel/depot in indolent and progressive metastatic intestinal or pancreatic NETs. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. Radiosynovectomy in rheumatic diseases

Author

Ćwikła, Jarosław B., Żbikowski, Piotr, Kwiatkowska, Brygida, Buscombe, John R., and Sudoł-Szopińska, Iwona

Subjects
musculoskeletal diseases, rheumatoid arthritis, osteoarthritis, lcsh:R5-920, lcsh:Medical technology, arthritis, lcsh:R855-855.5, radiosynovectomy, Review, synovitis, lcsh:Medicine (General)
Abstract

Radiosynovectomy is a safe and repeatable treatment method of chronic synovitis with synovial overgrowth and refractory chronic or acute inflammatory joint effusion. It consist in the intraarticular administration of a radioactive isotope in the form of a colloid causing the extinguishing of active synovitis. The radiocolloid causes permanent irradiation of the synovium with beta ray electron beams, which ultimately leads to its fibrosis and extinguishes the inflammatory process destroying the joint. The main indications for radiosynovectomy include chronic and acute arthritis in the course of systemic diseases, intraarticular bleeding in hemorrhagic diatheses (hemophilia), selected cases of osteoarthritis, recurrent effusions following surgery, e.g. arthroplasty, or other iatrogenic post-surgery complications causing arthritis. Radiosynovectomy is also performed in pigmented villonodular synovitis and crystal synovitis. The most common method used to determine the eligibility for radiosynovectomy is an ultrasound, which shows the location and activity of the thickened synovium. The administration of a radiocolloid into the joint, sheath or bursa should also be performed under the control of the ultrasound image, as this ensures a precise location of the puncture needle and full control of the isotope administration process. Clinical efficacy of radiosynovectomy depends on the proper qualification of patients for the procedure. The success rate of radiosynovectomy in common indications is 65-80%. It is confirmed by the visualization of avascular (fibrotic) synovium in follow-up ultrasound tests. The aim of this article is to present techniques and indications for the radiosynovectomy treatment.Radiosynowektomia jest bezpiecznym i powtarzalnym zabiegiem, polegającym na podaniu do jamy stawu lub pochewki ścięgnistej preparatu zawierającego izotop promieniotwórczy w formie radiokoloidu, powodujący wygaszenie aktywnego zapalenia błony maziowej. W następstwie trwałej inkorporacji radiokoloidu dochodzi do ciągłego napromieniowania błony maziowej strumieniami elektronów promieniowania beta, co w końcowym efekcie terapeutycznym prowadzi do jej zwłóknienia i tym samym zatrzymania procesu zapalnego, który jest przyczyną niszczenia stawu.Głównymi wskazaniami do radiosynowektomii są przewlekłe i ostre zapalenia stawów w przebiegu chorób układowych, krwawienia dostawowe w skazach krwotocznych, niektóre przypadki choroby zwyrodnieniowej stawów, nawracające wysięki po zabiegach operacyjnych, m.in. alloplastyce stawów, czy inne jatrogenne powikłania zabiegów operacyjnych powodujące zapalenie stawu. Radiosynowektomię wykonuje się także w przypadku barwnikowego kosmkowo-guzkowego zapalenia błony maziowej i zapaleń stawu wywołanych kryształami. Z reguły metodą kwalifikującą do radiosynowektomii jest ultrasonografia, obrazująca lokalizację i aktywność pogrubiałej błony maziowej. Również podawanie radiokoloidu do stawu, pochewki lub kaletki powinno być wykonywane pod kontrolą obrazu ultrasonograficznego, zapewnia to bowiem dokładną lokalizację igły punkcyjnej i pełną kontrolę procesu podawania izotopu. Skuteczność kliniczna radiosynowektomii zależy od właściwej kwalifikacji pacjentów do zabiegu; w typowych wskazaniach metoda ta umożliwia osiągnięcie znacznej poprawy u 65–80% chorych. Jej potwierdzeniem jest uwidocznienie w kontrolnym badaniu ultrasonograficznym nieunaczynionej (zwłókniałej) błony maziowej. Artykuł ma na celu przybliżenie czytelnikom techniki oraz wskazań do leczenia za pomocą radiosynowektomii.

Published
2014

31. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

Author

Matar, Somer, Malczewska, Anna, Oberg, Kjell, Bodei, Lisa, Aslanian, Harry, Lewczuk-Myślicka, Anna, Filosso, Pier Luigi, Suarez, Alejandro L., Kolasińska-Ćwikła, Agnieszka, Roffinella, Matteo, Kos-Kudła, Beata, Ćwikła, Jarosław B., Drozdov, Ignat A., Kidd, Mark, and Modlin, Irvin M.

Subjects
NEUROENDOCRINE tumors, CANCER, DIAGNOSIS, LUNG diseases, TUMOR markers
Abstract

Background: Identification of circulating tumor markers for clinical management in bronchopulmonary (BP) neuroendocrine tumors/neoplasms (NET/NEN) is of considerable clinical interest. Chromogranin A (CgA), a "universal" NET biomarker, is considered controversial as a circulating biomarker of BPNEN. Aim: Assess utility of CgA in the diagnosis and management of BPNEN in a multicentric study. Material and Methods: CgA diagnostic metrics were assessed in lung NET/NENs (n = 200) and controls (n = 140), randomly assigned to a Training and Test set (100 BPC and 70 controls in each). Assay specificity was evaluated in neoplastic lung disease (n = 137) and nonneoplastic lung disease (n = 77). CgA efficacy in predicting clinical status was evaluated in the combined set of 200 NET/NENs. CgA levels in bronchopulmonary neuroendocrine tumor (BPNET) subtypes (atypical [AC] vs. typical [TC]) and grade was examined. The clinical utility of an alteration of CgA levels (±25%) was evaluated in a subset of 49 BPNET over 12 months. CgA measurement was by NEOLISATM kit (EuroDiagnostica). Results: Sensitivity and specificity in the training set were 41/98%, respectively. Test set data were 42/87%. Training set area under receiver operator characteristic analysis differentiated BPC from control area under the curve (AUC) 0.61 ± 0.05 p = 0.015. Test set the data were AUC 0.58 ± 0.05, p = 0.076. In the combined set (n = 200), 67% BPNET/NEN (n = 134) had normal CgA levels. CgA levels did not distinguish histological subtypes (TC vs. AC, AUC 0.56 ± 0.04, p = 0.21), grade (p = 0.45–0.72), or progressive from stable disease (AUC 0.53 ± 0.05 p = 0.47). There was no correlation of CgA with Ki-67 index (Pearson r = 0.143, p = 0.14). For nonneoplastic diseases (chronic obstructive pulmonary disorder and idiopathic pulmonary fibrosis), CgA was elevated in 26–37%. For neoplastic disease (NSCLC, squamous cell carcinoma), CgA was elevated in 11–16%. The neuroendocrine SCLC also exhibited elevated CgA (50%). Elevated CgA was not useful for differentiating BPNET/NEN from these other pathologies. Monitoring BPNET/NEN over a 12-month period identified neither CgA levels per se nor changes in CgA were reflective of somatostatin analog treatment outcome/efficacy or the natural history of the disease (progression). Conclusions: Blood CgA levels are not clinically useful as a biomarker for lung BPNET/NEN. The low specificity and elevations in both nonneoplastic as well as other common neoplastic lung diseases identified limited clinical utility for this biomarker. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Zalecenia ogólne dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Author

Kos-Kudła, Beata, primary, Blicharz-Dorniak, Jolanta, additional, Strzelczyk, Janusz, additional, Bałdys-Waligórska, Agata, additional, Bednarczuk, Tomasz, additional, Bolanowski, Marek, additional, Boratyn-Nowicka, Agnieszka, additional, Borowska, Małgorzata, additional, Cichocki, Andrzej, additional, Ćwikła, Jarosław B., additional, Falconi, Massimo, additional, Foltyn, Wanda, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Barbara, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Król, Robert, additional, Królicki, Leszek, additional, Krzakowski, Maciej, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lampe, Paweł, additional, Lange, Dariusz, additional, Lewczuk-Myślicka, Anna, additional, Lewiński, Andrzej, additional, Lipiński, Michał, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Nasierowska-Guttmejer, Anna, additional, Nawrocki, Sergiusz, additional, Nowakowska-Duława, Ewa, additional, Pilch-Kowalczyk, Joanna, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Steinhof-Radwańska, Katarzyna, additional, Sworczak, Krzysztof, additional, Syrenicz, Anhelli, additional, Szawłowski, Andrzej, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, and Zieniewicz, Krzysztof, additional

Published
2017
Full Text
View/download PDF

36. Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Author

Lipiński, Michał, primary, Rydzewska, Grażyna, additional, Foltyn, Wanda, additional, Andrysiak-Mamos, Elżbieta, additional, Bałdys-Waligórska, Agata, additional, Bednarczuk, Tomasz, additional, Blicharz-Dorniak, Jolanta, additional, Bolanowski, Marek, additional, Boratyn-Nowicka, Agnieszka, additional, Borowska, Małgorzata, additional, Cichocki, Andrzej, additional, Ćwikła, Jarosław B., additional, Falconi, Massimo, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Barbara, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Król, Robert, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lampe, Paweł, additional, Lange, Dariusz, additional, Lewczuk-Myślicka, Anna, additional, Lewiński, Andrzej, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pilch-Kowalczyk, Joanna, additional, Poczkaj, Karolina, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Steinhof-Radwańska, Katarzyna, additional, Strzelczyk, Janusz, additional, Sworczak, Krzysztof, additional, Syrenicz, Anhelli, additional, Szawłowski, Andrzej, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, and Kos-Kudła, Beata, additional

Published
2017
Full Text
View/download PDF

37. Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Author

Starzyńska, Teresa, primary, Londzin-Olesik, Magdalena, additional, Bałdys-Waligórska, Agata, additional, Bednarczuk, Tomasz, additional, Blicharz-Dorniak, Jolanta, additional, Bolanowski, Marek, additional, Boratyn-Nowicka, Agnieszka, additional, Borowska, Małgorzata, additional, Cichocki, Andrzej, additional, Ćwikła, Jarosław B., additional, Deptała, Andrzej, additional, Falconi, Massimo, additional, Foltyn, Wanda, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Barbara, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Król, Robert, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lampe, Paweł, additional, Lange, Dariusz, additional, Lewczuk-Myślicka, Anna, additional, Lewiński, Andrzej, additional, Lipiński, Michał, additional, Marek, Bogdan, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pilch-Kowalczyk, Joanna, additional, Remiszewski, Piotr, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Steinhof-Radwańska, Katarzyna, additional, Strzelczyk, Janusz, additional, Sworczak, Krzysztof, additional, Syrenicz, Anhelli, additional, Szawłowski, Andrzej, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, Zgliczyński, Wojciech, additional, and Kos-Kudła, Beata, additional

Published
2017
Full Text
View/download PDF

38. Nowotwory neuroendokrynne trzustki — zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)

Author

Kos-Kudła, Beata, primary, Rosiek, Violetta, additional, Borowska, Małgorzata, additional, Bałdys-Waligórska, Agata, additional, Bednarczuk, Tomasz, additional, Blicharz-Dorniak, Jolanta, additional, Bolanowski, Marek, additional, Boratyn-Nowicka, Agnieszka, additional, Cichocki, Andrzej, additional, Ćwikła, Jarosław B., additional, Falconi, Massimo, additional, Foltyn, Wanda, additional, Handkiewicz-Junak, Foltyn, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Barbara, additional, Jarząb, Michał, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Król, Robert, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lampe, Paweł, additional, Lange, Dariusz, additional, Lewczuk-Myślicka, Anna, additional, Lewiński, Andrzej, additional, Lipiński, Michał, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pilch-Kowalczyk, Joanna, additional, Ruchała, Marek, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Steinhof-Radwańska, Katarzyna, additional, Strzelczyk, Janusz, additional, Sworczak, Krzysztof, additional, Syrenicz, Anhelli, additional, Szawłowski, Andrzej, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zemczak, Anna, additional, and Zgliczyński, Wojciech, additional

Published
2017
Full Text
View/download PDF

39. Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Author

Bednarczuk, Tomasz, primary, Bolanowski, Marek, additional, Zemczak, Anna, additional, Bałdys-Waligórska, Agata, additional, Blicharz-Dorniak, Jolanta, additional, Boratyn-Nowicka, Agnieszka, additional, Borowska, Małgorzata, additional, Cichocki, Andrzej, additional, Ćwikła, Jarosław B., additional, Falconi, Massimo, additional, Foltyn, Wanda, additional, Handkiewicz-Junak, Daria, additional, Hubalewska-Dydejczyk, Alicja, additional, Jarząb, Barbara, additional, Junik, Roman, additional, Kajdaniuk, Dariusz, additional, Kamiński, Grzegorz, additional, Kolasińska-Ćwikła, Agnieszka, additional, Kowalska, Aldona, additional, Król, Robert, additional, Królicki, Leszek, additional, Kunikowska, Jolanta, additional, Kuśnierz, Katarzyna, additional, Lampe, Paweł, additional, Lange, Dariusz, additional, Lewczuk-Myślicka, Anna, additional, Lewiński, Andrzej, additional, Lipiński, Michał, additional, Londzin-Olesik, Magdalena, additional, Marek, Bogdan, additional, Nasierowska-Guttmejer, Anna, additional, Nowakowska-Duława, Ewa, additional, Pałucki, Jakub, additional, Pilch-Kowalczyk, Joanna, additional, Rosiek, Violetta, additional, Ruchała, Marek, additional, Siemińska, Lucyna, additional, Sowa-Staszczak, Anna, additional, Starzyńska, Teresa, additional, Steinhof-Radwańska, Katarzyna, additional, Strzelczyk, Janusz, additional, Sworczak, Krzysztof, additional, Syrenicz, Anhelli, additional, Szawłowski, Andrzej, additional, Szczepkowski, Marek, additional, Wachuła, Ewa, additional, Zajęcki, Wojciech, additional, Zgliczyński, Wojciech, additional, and Kos-Kudła, Beata, additional

Published
2017
Full Text
View/download PDF

42. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).

Author

Kolasińska-Ćwikła, Agnieszka D., Konsek, Sonia J., Buscombe, John R., Maciejkiewicz, Katarzyna, Cichocki, Andrzej, Roszkowska-Purska, Katarzyna, Sawicki, Łukasz, Tenderenda, Michał, and Ćwikła, Jarosław B.

Subjects
CELL receptors, DIAGNOSTIC errors, NEUROENDOCRINE tumors, PANCREATIC tumors, RADIONUCLIDE imaging, RADIOISOTOPES, SOMATOSTATIN, TECHNETIUM, TUMOR classification, SINGLE-photon emission computed tomography, RETROSPECTIVE studies, TUMOR grading
Abstract

BACKGROUND: Neuroendocrine neoplasms of the pancreas (p-NEN) are common gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in initial detection of p-NEN, evaluation of tumour extent and as imaging follow-up after radical surgery in patients with confirmed well (NETG1) or moderately (NETG2) differentiated p-NEN based on pathological WHO 2017 classification. MATERIAL AND METHODS: Overall 281 patients with confirmed p-NEN were enrolled. The SRS was performed to evaluate primary p-NEN, to assess clinical stage of disease, based on current World Health Organization (WHO) classification and during clinical follow-up. A total of 829 examinations were performed over time in these 281 patients using 99mTc HYNICTOC. Images were acquired between 1-3 h after i.v. injection of radiotracer. Initially whole body WB-SPECT and then WB-SPECT/CT with standard iterative reconstruction were used. RESULTS: There were 159 patients with NETG1 (57%) and 122 subjects with NETG2 (43%). The female to male ratio was 1.1:1. In 68 patients (22%) with NETG1/G2 eighty-seven SRSs (10%) were performed to confirm initial diagnosis. SRS results were as follow: true positive (TP) = 84 (97%), false negative (FN) = 3 (3%), no true negative (TN) or false positive (FP) results of SRS examination (sensitivity of SRS per patient was 96%). In 198 subjects (66%) SRS was used in evaluation and re-evaluation of the clinical stage. A total of 661 (80%) examinations were carried out in these patients. There were TP = 514 (77%), TN = 136 (21%), FN = 7 (1%) and FP = 4 (1%) results. The sensitivity and specificity per patient were: 96% and 95%. The sensitivity and specificity per study were: 98% and 97%. In 35 patients (12%) SRS was used as imaging follow-up after radical surgery; there were overall 81 examinations (10%) performed. There were 76 (91%) TN results of SRS examinations and in 4 patients we identified recurrence (TP). In total, which consists of initial diagnosis/staging and patient follow-up, the sensitivity of SRS was 96% and specificity 97% per patient and per study sensitivity and specificity was 98%. CONCLUSIONS: SRS using 99mTc HYNICTOC acquired in WB-SPECT or WB-SPECT/CT techniques is an excellent imaging modality in detection of primary NETG1/G2 p-NEN. Our study confirms that SRS has high sensitivity and specificity, as a result has tremendous value as an examination method to assess clinical stage of disease and as an imaging follow-up after radical treatment. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Author

Caplin, Martyn E, primary, Pavel, Marianne, additional, Ćwikła, Jarosław B, additional, Phan, Alexandria T, additional, Raderer, Markus, additional, Sedláčková, Eva, additional, Cadiot, Guillaume, additional, Wolin, Edward M, additional, Capdevila, Jaume, additional, Wall, Lucy, additional, Rindi, Guido, additional, Langley, Alison, additional, Martinez, Séverine, additional, Gomez-Panzani, Edda, additional, Ruszniewski, Philippe, additional, and _, _, additional

Published
2016
Full Text
View/download PDF

45. Peptide receptor radionuclide therapy for advanced gastroenteropancreatic neuroendocrine tumors -- from oncology perspective.

Author

Kolasińska-Ćwikła, Agnieszka, Łowczak, Anna, Maciejkiewicz, Katarzyna, and Ćwikła, Jarosław B.

Subjects
KIDNEY disease prevention, KIDNEY disease risk factors, PEPTIDES, RADIOISOTOPE therapy, CELL receptors, ONCOLOGY, BONE marrow diseases, AMINO acids, BIOMARKERS, CELL membranes, CHRONIC diseases, DRUG side effects, ENDOCRINE diseases, ENDOCRINE gland tumors, FATIGUE (Physiology), METALS, METASTASIS, NERVOUS system tumors, PANCREATIC tumors, QUALITY of life, QUESTIONNAIRES, RADIOISOTOPES, RADIOTHERAPY, SOMATOSTATIN, SURVIVAL, TRANSITION metals, TUMOR classification, GASTROINTESTINAL tumors, DISEASE exacerbation, DISEASE progression, PSYCHOLOGY, PREVENTION, THERAPEUTICS
Abstract

Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue -- SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (so called diffuse neuroendocrine system). The goal of PRRT is irradiation of tumour cells, via direct binding into specific receptor, somatostatin receptors (SSTR) family, overexpressed on the cell membrane of the primary tumours as well as on the metastasis. Over many years of clinical use of PRRT with 90Y and current with 177Lu DOTA conjugated somatostatin analogues proved to be efficient therapy option for NETs, with tumour responses, base on radiological evaluation. Also, a clinical response with symptoms relief and improvement in quality of life based on standard EORTC questioners is seen. Additional, common NET biomarker reduction and, ultimately, an impact on overall survival (OS) of patients with advanced non-resectable often progressive NEN can be expected. PRRT with 90Y or 177Lu-labelled peptides is generally well tolerated by most of the patients. The acute side effects (Adverse Events -- AEs) are usually mild; most of them are related to the co-administration of amino acids (AA), such as nausea and vomiting. Others are related to the radioisotopes, such as fatigue or the exacerbation of endocrine syndromes, which are very rarely and they occurs, only in patients with functional tumours and large tumours burden. Chronic and permanent damage has an effect on target organs, particularly the kidneys and the bone marrow, which are generally mild. Currently, when 177Lu DOTATATE is used, the potential risk to kidney damage is significantly reduced, compared to the previous usage of 90Y labelled analogues. Up to now, kidney and bone marrow toxicity limits the dose of radioactivity of PRRT. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

46. The use of 67Ga scintigraphy in patients with sarcoidosis.

Author

Malinowska, Ewa, Doboszyńska, Anna G. G., Śliwińska, Anna M., Buscombe, John R., Kulesza, Grzegorz, Moczulska, Beata, and Ćwikła, Jarosław B.

Abstract

Sarcoidosis is a systemic disease of unknown aetiology characterised by the formation of noncaseating granulomas in various organs and tissues. The various imaging modalities that are useful in the investigation of lesions, staging and establishing indications for treatment include: conventional radiography, CT, MRI, and scintigraphy with 67Ga, 201Tl, 99mTc sestamibi, and somatostatin receptor scintigraphy (SRS) as well as 18F-FDG-PET/CT. This paper discusses the most commonly used technique of the scintigraphic, gallium (67Ga) citrate) and its role in the evaluation and monitoring of patients with sarcoidosis. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. Ocena bezpieczeństwa i efektywność jabłczanu sunitynibu w przerzutowych guzach neuroendokrynnych trzustki (NEN G1/G2) w zależności od liczby i rodzaju wcześniejszych linii terapeutycznych — doniesienie wstępne

Author

Wachuła, Ewa, primary, Ćwikła, Jarosław B., additional, Rogowski, Wojciech, additional, Boratyn-Nowicka, Agnieszka, additional, Szabłowska-Siwik, Sylwia, additional, Piątek, Michał, additional, Zemczak, Anna, additional, Michalik, Barbara, additional, Jarząb, Barbara, additional, Nawrocki, Sergiusz, additional, and Kos-Kudła, Beata, additional

Published
2015
Full Text
View/download PDF

48. Usefulness of Somatostatin Receptor Scintigraphy (99mTc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography

Author

Michałowska, Ilona, primary, Ćwikła, Jarosław B., additional, Pęczkowska, Mariola, additional, Furmanek, Mariusz I., additional, Buscombe, John R., additional, Michalski, Wojciech, additional, Prejbisz, Aleksander, additional, Szperl, Małgorzata, additional, Malinoc, Angelica, additional, Moczulski, Dariusz, additional, Szutkowski, Zbigniew, additional, Kawecki, Andrzej, additional, Antoniewicz, Jolanta, additional, Pęczkowski, Piotr, additional, Lewczuk, Anna, additional, Otto, Maciej, additional, Cichocki, Andrzej, additional, Bednarek-Tupikowska, Grażyna, additional, Kabat, Marek, additional, Janaszek-Sitkowska, Hanna, additional, Przybyłowska, Katarzyna, additional, Janas, Jadwiga, additional, Neumann, Hartmut P.H., additional, and Januszewicz, Andrzej, additional

Published
2015
Full Text
View/download PDF

49. Colorectal neuroendocrine neoplasms -- management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).

Author

Starzyńska, Teresa, Londzin-Olesik, Magdalena, Bałdys-Waligórska, Agata, Bednarczuk, Tomasz, Blicharz-Dorniak, Jolanta, Bolanowski, Marek, Boratyn-Nowicka, Agnieszka, Borowska, Małgorzata, Cichocki, Andrzej, Ćwikła, Jarosław B., Deptała, Andrzej, Falconi, Massiomo, Foltyn, Wanda, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Jarząb, Barbara, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, and Kolasińska-Ćwikła, Agnieszka

Published
2017
Full Text
View/download PDF

50. Neuroendocrine neoplasms of the small intestine and appendix -- management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).

Author

Bednarczuk, Tomasz, Bolanowski, Marek, Zemczak, Anna, Bałdys-Waligórska, Agata, Blicharz-Dorniak, Jolanta, Boratyn-Nowicka, Agnieszka, Borowska, Małgorzata, Cichocki, Andrzej, Ćwikła, Jarosław B., Falconi, Massimo, Foltyn, Wanda, Handkiewicz-Junak, Daria, Hubalewska-Dydejczyk, Alicja, Jarząb, Barbara, Junik, Roman, Kajdaniuk, Dariusz, Kamiński, Grzegorz, Kolasińska-Ćwikła, Agnieszka, Kowalska, Aldona, and Król, Robert

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results